Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ACHE | P22303 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | G6PD | P11413 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29980735 | 0.93 | CYP3A4 (0.87) | CYP3A4HPGDACHEPOLBKMT2A | |
| SCHEMBL11067587 | 0.88 | CYP3A4 (0.79) | CYP3A4HPGDACHEPOLBKMT2A | |
| SCHEMBL6493747 | 0.88 | CYP3A4 (0.79) | CYP3A4HPGDACHEPOLBKMT2A | |
| Methyl Orsellinate SCHEMBL370816 | 0.85 | CYP3A4 (1.00) | CYP3A4HPGDACHEPOLBKMT2A | |
| Ethyl Everninate SCHEMBL31233848 | 0.84 | CYP3A4 (1.00) | CYP3A4HPGDACHEPOLBKMT2A | |
| Ethyl Everninate SCHEMBL1640418 | 0.84 | CYP3A4 (1.00) | CYP3A4HPGDACHEPOLBKMT2A | |
| SCHEMBL4263528 | 0.83 | CYP3A4 (0.71) | CYP3A4HPGDACHEPOLBKMT2A | |
| SCHEMBL30916607 | 0.83 | CYP3A4 (0.71) | CYP3A4HPGDACHEPOLBKMT2A | |
| Everninic Acid SCHEMBL609931 | 0.83 | POLB (0.81) | CYP3A4HPGDACHEPOLBKMT2A | |
| SCHEMBL12553515 | 0.82 | CYP3A4 (0.68) | CYP3A4HPGDACHEPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023064318-A1 | BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE | Natural Extraction Systems, LLC (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022040799-A1 | ANTIMICROBIAL COMPOSITION | GP TECH INOVASYON TEKNOLOJI VE ARASTIRMA A.S (TR) | 2022-03-03 | — | — | WO | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| CN-110568106-B | Quantitative detection method for turpentine substances in turpentine plants or extracts | 云南中烟工业有限责任公司 | 2021-08-03 | — | — | CN | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260014091-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250366979-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250366978-A1 | DEVICES AND METHODS OF MAKING AND USE THEREOF | METHODIST HOSPITAL (US) | 2025-12-04 | — | — | US | disclosed |
| US-20050276815-A1 | Antiviral activity from medicinal mushrooms | TURTLE BEAR HOLDINGS, LLC | 2005-12-15 | — | — | US | disclosed |
| US-20050238655-A1 | Antiviral activity from medicinal mushrooms | TURTLE BEAR HOLDINGS, LLC | 2005-10-27 | — | — | US | disclosed |
| WO-2005067955-A1 | ANTIMICROBIAL ACTIVITY FROM MEDICINAL MUSHROOMS | STAMETS PAUL (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-0446925-B1 | Process for the preparation of beta-resorcylic acid derivatives | CONSORTIUM ELEKTROCHEM IND (DE) | 1995-06-21 | — | — | EP | disclosed |
| US-5171878-A | Reacting a diketene with a beta-keto ester in presence of alkaline earth compound; perfumes | CONSORTIUM FOR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1992-12-15 | — | — | US | disclosed |
| EP-0446925-A2 | Process for the preparation of beta-resorcylic acid derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014091-A1 | COMPOSITIONS AND METHODS OF MAKING AND USE THEREOF | ERBB3, ERBB2, EGFR | CYP3A4 2945/4885HPGD 687/4885ACHE 1111/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | CYP3A4 3571/4885HPGD 533/4885ACHE 1902/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | CYP3A4 2837/4885HPGD 950/4885ACHE 1620/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | CYP3A4 1840/4885HPGD 329/4885ACHE 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.